An activity sensor sensitive to enzymes indicative of tissue condition are co-administered with control or normalizing activity sensors providing levels of the same enzyme in other tissues or levels of control enzymes indicative of assay success. Levels of control reporters can be used to normalize activity sensor data across samples such as in analyte velocity analyses. Control reporters can also be used to differentiate localized enzyme activity from systemic activity and to confirm activity sensor localization or to troubleshoot activity sensor uptake problems. Activity sensors and controls sensitive to immunological enzymes are particularly useful in assessing immuno-oncology treatments.

The present invention relates to the methods and products for detection of colorectal cancer. Additionally, the present invention relates to methods and products for determining the probability, risk or incidence of colorectal cancer and of colorectal cancer metastasis. The products and methods of the present invention include detecting the level of expression of COL10A1 or MMP11, in combination, from samples, including tissue samples, from humans who currently have been diagnosed with cancer or who were previously diagnosed with cancer and those who are thought to have cancer and are undergoing diagnosis.

Methods for treating chronic wounds with an amniotic fluid having a therapeutically effective amount of tissue inhibitors of matrix metalloproteinases (TIMPs) are described. The amniotic fluid can be obtained from a female donor during a period of gestation when the concentration of endogenous TIMPs are at or near their maximum level. The methods described herein are particularly useful for promoting wound healing in chronic wounds having elevated protease activity, such as increased amounts or specific activity of matrix metalloproteinases.

The present application relates to a method for diagnosis of endometriosis in a subject, comprising the steps of (i) determining the level of β2-Microglobulin protein (β2M) as a biomarker in a sample of said subject to be diagnosed; (ii) comparing the biomarker level as determined in steps (i) to a respective control level derived from one or more subject without endometriosis;
wherein a reduced level as compared to the respective control level of β2M is indicative for the presence of endometriosis in said subject to be diagnosed. In particular, the application relates to a diagnostic classifier comprising a combination of a plurality of biomarkers selected from the group consisting of β2M protein level, CA19-9 level, CA125 protein level, PON-1 activity, MMP1 protein level and MMP2 protein level.

A method for treating cystitis, in particular acute cystitis, comprising administering to a patient in need thereof, an effective amount of a reagent selected from the group consisting of IL-1β inhibitors and MMP inhibitors, or proteins selected from ASC or NLRP-3. Diagnostic methods are also described and claimed.

The present invention relates to the methods and products for detection of colorectal cancer. Additionally, the present invention relates to methods and products for determining the probability, risk or incidence of colorectal cancer and of colorectal cancer metastasis. The products and methods of the present invention include detecting the level of expression of COL10A1 or MMP11, in combination, from samples, including tissue samples, from humans who currently have been diagnosed with cancer or who were previously diagnosed with cancer and those who are thought to have cancer and are undergoing diagnosis.

Non-invasive methods of risk stratification and treatment of bladder cancer in a subject are based on evaluating D-dimer in a urine sample of the subject, and assay systems thereof for evaluation of D-dimer in the urine sample.

The present application relates to a composition for preventing or treating osteoarthritis, including an osteoclast-associated Ig-like receptor (OSCAR) protein inhibitor, a polynucleotide encoding an anti-OSCAR antibody or a fragment thereof, and an OSCAR protein inhibitor screening method. According to embodiments of the present application, the anti-osteoclast-associated Ig-like receptor (OSCAR) antibody or a fragment thereof of the present application may prevent or treat osteoarthritis through a mechanism for inhibiting the OSCAR-collagen interaction in chondrocytes, and an OSCAR protein inhibitor having an excellent effect of inhibiting the OSCAR-collagen interaction can be screened by using the OSCAR protein inhibitor screening method of the present application.

Disclosed is a system, a kit, a use and an in vitro method for assessing whether a human patient suffering from periodontitis has mild periodontitis or advanced periodontitis. The system and method are based on the insight to apply a clustering technique to a reference set of patient data, and then further discriminating the sets of bio markers to be applied. The clusters are determined on the basis of the biomarkers Hepatocyte Growth Factor (HGF), Matrix metalloproteinase 8 (MMP8), and Matrix metalloproteinase 9 (MMP9). The actual classification of the patient is done on the basis of the measurement of the concentrations of either of two sets of biomarkers. For one cluster these are Interleukin-1β (IL1β), Interleukin-6 (IL6), and Collagen Telopeptide. For the other cluster, these are HGF and metallopeptidase inhibitor 1 (TIMP1).

The present disclosure provides methods, devices, kits, and agents for the treatment of aging and aging related diseases and disorders and related systems and methods.